Anaemia is a major comorbidity in people with end stage renal disease (ESRD) and often dependent on blood transfusions and erythropoietin stimulating agents (ESA), for management of anaemia. ESA effectively increase haemoglobin and improve quality of life in patients on dialysis but adds up enormous cost burden. ESA takes care of the deficiency of Erythropoietin […]